LINCOLNSHIRE, Ill.--(BUSINESS WIRE)--BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX) today announced the issuance of a new U.S. patent covering the “method of use” of LibiGel (testosterone gel) for treating female sexual dysfunction (FSD) and hypoactive sexual desire disorder (HSDD). The patent covers methods for treating FSD and HSDD and also includes using a metered dosage device to deliver the defined dose of the testosterone formulation in LibiGel. U.S. Patent No. 8,067,399, which issued today, will expire on December 29, 2028. The two named inventors of this new patent are a current and a former employee of BioSante.
